Evaluation of Denosumab in Combination With Immune Checkpoint Inhibitors in Patients With Unresectable or Metastatic Melanoma

NCT03161756 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

UNKNOWN

Status

72

Enrollment

OTHER

Sponsor class

Conditions

Melanoma Stage Iv
Melanoma Stage Iii
Melanoma

Interventions

DRUG: Denosumab
DRUG: Nivolumab
DRUG: Ipilimumab

Sponsor

Melanoma and Skin Cancer Trials Limited

Collaborators

[object Object]
[object Object]
[object Object]